Review
Medicine, General & Internal
Elena Yukie Uebayashi, Hideaki Okajima, Miki Yamamoto, Eri Ogawa, Tatsuya Okamoto, Hironori Haga, Etsurou Hatano
Summary: Antibody-mediated rejection (AMR) of liver allograft transplantation has gained clinical awareness as a potential cause of chronic liver injury and graft failure. The accurate incidence, diagnostic criteria, and treatment protocols of chronic AMR in pediatric patients remain unclear and further research is needed.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Gastroenterology & Hepatology
Brian T. Lee, M. Isabel Fiel, Thomas D. Schiano
Summary: Antibody-mediated rejection after liver transplantation is a lesser recognized cause of allograft injury, with challenges in timely diagnosis and treatment, highlighting the need for further research and development in this area.
JOURNAL OF HEPATOLOGY
(2021)
Article
Multidisciplinary Sciences
Bertrand Chauveau, Antoine Garric, Sylvaine Di Tommaso, Anne-Aurelie Raymond, Jonathan Visentin, Agathe Vermorel, Nathalie Dugot-Senant, Julie Dechanet-Merville, Jean-Paul Duong Van Huyen, Marion Rabant, Lionel Couzi, Frederic Saltel, Pierre Merville
Summary: This study utilized three interferon-related proteins in immunohistochemical analysis of kidney allograft biopsies, supplemented by a deep learning framework, to assist in the diagnosis of antibody-mediated rejection. The results showed promising diagnostic performance and reproducibility of these proteins with deep learning technology, effectively addressing the diagnostic challenges of ABMR.
SCIENTIFIC REPORTS
(2022)
Review
Immunology
Lara Cabezas, Thomas Jouve, Paolo Malvezzi, Benedicte Janbon, Diane Giovannini, Lionel Rostaing, Johan Noble
Summary: Chronic kidney disease is a significant public-health problem, and kidney transplantation is a better alternative to dialysis. Antibody-mediated rejection is a major complication following kidney transplantation. TCZ appears to be a safe and effective treatment for managing antibody-mediated rejection and reducing injury.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Medicine, General & Internal
Farah Abuazzam, Casey Dubrawka, Tarek Abdulhadi, Gwendolyn Amurao, Louai Alrata, Dema Yaseen Alsabbagh, Omar Alomar, Tarek Alhamad
Summary: Despite advances in immunosuppressive medications, antibody-mediated rejection (AMR) remains a major cause of kidney allograft failure. Recent developments in understanding the pathophysiology of AMR and new therapeutic options have emerged. Surveillance protocols using donor-derived cell-free DNA and gene profile testing have allowed for early detection of AMR. Ongoing clinical trials offer opportunities for improving outcomes in kidney transplant recipients.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, General & Internal
Hoa Le Mai, Nicolas Degauque, Sabine Le Bot, Marie Rimbert, Karine Renaudin, Richard Danger, Florent Le Borgne, Clarisse Kerleau, Gaelle Tilly, Anais Vivet, Florent Delbos, Alexandre Walencik, Magali Giral, Sophie Brouard
Summary: The study found that the percentage and absolute number of CD28-CD8+ T cells were significantly increased in kidney transplant patients with antibody-mediated rejection (ABMR). Moreover, CD28-CD8+ T cells from patients with ABMR showed a more rigorous response to stimulation compared to their CD28+ counterparts. These findings suggest that differentiated CD28-CD8+ T cells, with increased frequency, number, and function, may play a role in the pathobiology of ABMR.
Article
Immunology
Tetsuya Tajima, Koichiro Hata, Jiro Kusakabe, Hidetaka Miyauchi, Joshua Sam Badshah, Shoichi Kageyama, Xiangdong Zhao, Sung-Kwon Kim, Tatsuaki Tsuruyama, Varvara A. Kirchner, Takeshi Watanabe, Shinji Uemoto, Etsuro Hatano
Summary: We developed a rat model of liver transplantation antibody-mediated rejection (AMR) and demonstrated the effectiveness of anti-C5 antibody for treating this rejection.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Konstantin Doberer, Johannes Klaeger, Guido A. Gualdoni, Katharina A. Mayer, Farsad Eskandary, Evan A. Farkash, Hermine Agis, Thomas Reiter, Roman Reindl-Schwaighofer, Markus Wahrmann, Gerald Cohen, Helmuth Haslacher, Gregor Bond, Ingrid Simonitsch-Klupp, Philip F. Halloran, Georg A. Boehmig
Summary: The study highlights the potential of targeting CD38 for plasma cell and NK cell depletion in treating AMR. The use of daratumumab in a kidney allograft recipient with chronic active AMR led to significant improvements in immune cell counts, donor-specific antibody levels, and rejection-related gene expression patterns. This innovative treatment concept shows promise for future trials in organ transplantation research.
Article
Biochemistry & Molecular Biology
Bertrand Chauveau, Anne-Aurelie Raymond, Sylvaine Di Tommaso, Jonathan Visentin, Agathe Vermorel, Nathalie Dugot-Senant, Cyril Dourthe, Jean-William Dupuy, Julie Dechanet-Merville, Jean-Paul Duong Van Huyen, Marion Rabant, Lionel Couzi, Frederic Saltel, Pierre Merville
Summary: This study used proteomics to investigate the glomerular proteome modification in antibody-mediated rejection (ABMR) in kidney transplantation. It identified several proteins related to cellular stress, leukocyte activation, and tissue remodeling that were deregulated in ABMR. These findings may have implications for the diagnosis and treatment of ABMR.
Article
Cell Biology
Fei Han, Qipeng Sun, Zhengyu Huang, Heng Li, Maolin Ma, Tao Liao, Zihuang Luo, Lingling Zheng, Nana Zhang, Nan Chen, Liangqing Hong, Ning Na, Qiquan Sun
Summary: The study reveals that donor plasma mitochondrial DNA (dmtDNA) levels are correlated with the occurrence of antibody-mediated rejection (ABMR) in renal allograft recipients. Higher dmtDNA levels are associated with acute rejection and ABMR, presenting dmtDNA as a potential predictive marker for ABMR in organ evaluation.
Article
Medicine, General & Internal
Capucine Arrive, Marvin Jacquet, Elodie Gautier-Veyret, Thomas Jouve, Johan Noble, Dorothee Lombardo, Lionel Rostaing, Francoise Stanke-Labesque
Summary: The study suggests that early exposure to tocilizumab may be associated with macroalbuminuria within the first six months in patients with chronic antibody-mediated rejection (CAMR) of kidney transplant.
JOURNAL OF CLINICAL MEDICINE
(2023)
Editorial Material
Biochemistry & Molecular Biology
Nissrin Alachkar, Nada Alachkar
Summary: Diagnosing kidney allograft rejection is complex and subjective, but an automated Banff classification could make assessment easier and improve accuracy.
Article
Urology & Nephrology
Brian J. Nankivell, Meena Shingde, Chow H. P'Ng, Ankit Sharma
Summary: This study suggests that arterial C4d (C4d(art)) immunoperoxidase deposition may serve as a suggestive biomarker for antibody-mediated vascular rejection. Inclusion of C4d(art) in the diagnostic schema improves the sensitivity and accuracy of diagnosis for antibody-mediated vascular rejection and aids in the etiologic classification of arteritis.
KIDNEY INTERNATIONAL REPORTS
(2022)
Article
Urology & Nephrology
Brian J. Nankivell, Chow H. P'Ng, Meena Shingde
Summary: C4d(glom) is a promising diagnostic biomarker of endothelial interaction with antibody, which improves the immunologic classification of transplant glomerulopathy and enhances the accuracy of diagnosing late antibody-mediated rejection.
KIDNEY INTERNATIONAL REPORTS
(2022)
Article
Immunology
Philip F. Halloran, Jeff Reeve, Katelynn S. Madill-Thomsen, Zachary Demko, Adam Prewett, Philippe Gauthier, Paul Billings, Christopher Lawrence, Dave Lowe, Luis G. Hidalgo
Summary: This study analyzed the triple results of 280 kidney transplant biopsies, focusing on the question of dd-cfDNA levels in DSA-negative antibody-mediated rejection (AMR). The findings showed that DSA-negative AMR had moderately decreased AMR-associated features compared with DSA-positive AMR, but similarly elevated dd-cfDNA levels. Therefore, dd-cfDNA is superior to DSA in predicting AMR in this population, but the optimal predictions require both dd-cfDNA and DSA.